|
Virtual Meetings 2022
Meet The Professor: Optimizing the Management of HER2-Positive Breast CancerFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Lisa A Carey, MD, ScM L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research Deputy Director for Clinical Sciences Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina Nancy U Lin, MD Associate Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Mark D Pegram, MD Susy Yuan-Huey Hung Endowed Professor of Oncology Director, Clinical and Translational Research Unit Associate Dean for Clinical Research Quality Stanford University School of Medicine Associate Director for Clinical Research Stanford Comprehensive Cancer Institute Stanford, California SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Seagen Inc. Agenda
MODULE 1: Optimal Management of HER2-Positive Localized Breast Cancer MODULE 2: Evolving Treatment Paradigm for HER2-Positive and HER2-Low Metastatic Disease MODULE 3: Treatment Approaches for Patients with HER2-Positive Breast Cancer and Brain Metastases
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Dr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Lin — Consulting Agreements: Affinia Therapeutics, Aleta Biotherapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Denali Therapeutics, Janssen Biotech Inc, Olema Oncology, Prelude Therapeutics, Puma Biotechnology Inc, Seagen Inc, Voyager Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Merck, Olema Oncology, Pfizer Inc, Seagen Inc, Zion Pharmaceuticals. Dr Pegram — Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Halozyme Inc, Pfizer Inc, Sanofi, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biotheranostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halozyme Inc, Seagen Inc; Contracted Research: Pfizer Inc; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Nonrelevant Financial Relationship: Spouse employed by Rain Therapeutics Inc.SURVEY PARTICIPANTS — Adam M Brufsky, MD, PhD — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi, Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP. Professor Giuseppe Curigliano, MD, PhD — Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc; Consulting Agreement: Menarini Group; Data and Safety Monitoring Board/Committee: Novartis; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Pfizer Inc. Joyce O’Shaughnessy, MD — Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly, Pfizer Inc, Seagen Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Seagen Inc. |